Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Allying on ALRN-6924
December 2018
SHARING OPTIONS:

WATERTOWN, Mass.—Aileron Therapeutics and the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have united under an agreement to conduct an open-label, multi-center, pediatric Phase 1 clinical trial of Aileron’s lead drug candidate, ALRN-6924. The trial will evaluate ALRN-6924 in children with solid tumors, and ALRN-6924 plus cytarabine in children with acute leukemia, in two dose-escalation cohorts, with a third cohort being biomarker-enriched.
 
“MDMX and MDM2 play a role in many cancers, and our dual inhibitor of MDMX and MDM2, ALRN-6924, has shown in clinical trials that it can achieve responses in cancer patients,” said Dr. Manuel Aivado, CEO of Aileron Therapeutics. “We are thankful for the opportunity to provide ALRN-6924 to relapsed and refractory pediatric patients in an effort to improve outcomes for these children.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.